It is trading at $9.24 which is just over the 50 day moving average of $8.67 and which is impressively higher than the 200 day moving average of $8.23. The 50 day moving average went up $0.57 or +6.61% whereas the 200 day moving average was up $1.01 or +12.26%. Trading was heavy with 269K shares changing hands by the end of trading on Tuesday. Volume was up 128.95% over the stocks average daily volume.
Traders are a little more bullish on shares of the company recently considering the downtick in short interest. The company realized a fall in short interest between September 15, 2017 and September 29, 2017 of -8.04%. Short shares decreased from 665,131 to 611,644 over that timeframe. Days to cover decreased from 6.0 to 3.0 and the percentage of shorted shares was 0.02% on September 29.
Additionally, here are a few investment firms who have increased or decreased their stake in (VCYT). As of quarter end Venbio Select Advisor LLC had acquired 597 shares growing its holdings by 0.1%. The value of the investment in Veracyte, Inc. decreased from $8,326,000 to $7,560,000 decreasing 9.2% quarter to quarter. Cutler Group LP trimmed its investment by shedding 52,607 shares a decrease of 96.3%. Cutler Group LP controls 2,000 shares with a value of $0. The value of the position overall is down by 100.0%.
Meeder Asset Management Inc expanded its ownership by buying 437 shares an increase of 54.4% in the quarter. Meeder Asset Management Inc claims 1,240 shares valued at $11,000. The total value of its holdings increased 57.1%. As of the end of the quarter Bank Of Montreal /can/ had bought a total of 204 shares growing its stake by 2.7%. The value of the investment in VCYT went from $62,000 to $68,000 a change of 9.7% quarter over quarter.
In the latest earnings report the EPS was $-0.80 and is projected to be $-0.92 for the current year with 33,893,000 shares currently outstanding. Next quarter’s EPS is forecasted to be $-0.19 and the next full year EPS is projected to be $-0.58.
Veracyte, Inc., launched on August 15, 2006, is a genomic diagnostics company. The Company uses genomic technology to resolve diagnostic ambiguity. The Company targets diseases in which patients undergo invasive diagnostic procedures. The Company?s products combine genomic technology, clinical science and machine learning. The Company commercializes over three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis. The Company?s commercial solution, the Afirma Thyroid fine needle aspiration (FNA) Analysis, centers on the Afirma Gene Expression Classifier (GEC). The Afirma GEC is offered directly or as part of a solution that also includes cytopathology. The Company markets and sells Afirma in the United States, in select foreign countries..